Common Contracts
1 similar null contracts
Sprint Bioscience AB (publ) has licensed the global rights to its cancer program VADA (VRK1) to Day One Biopharmaceuticals Inc. The total potential value of the agreement amounts to US$ 316 million plus single-digit royalties on sales of a future drug...August 16th, 2023
In addition to the upfront payment and research funding, Sprint Bioscience is entitled to payments linked to predefined milestones during the program's continued development, its regulatory process, and commercialization of a potential drug. The total value of these payments is up to US$ 313 million.
